Alnylam Pharmaceuticals (ALNY) Change in Cash (2009 - 2026)

Alnylam Pharmaceuticals has reported Change in Cash for 18 years, with the latest figure at $53.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash changed 0.03% year-over-year to $53.6 million; the trailing twelve-month figure through Mar 2026 stood at $690.2 million (up 104.48% YoY), and the FY2025 full-year result was $690.2 million, up 348.83% from the prior year.
• Change in Cash for Q1 2026 stood at $53.6 million, down from $166.0 million in the prior quarter.
• The five-year high for Change in Cash was $497.7 million in Q3 2022, with the low at -$285.9 million in Q1 2022.
• Historically, Change in Cash has averaged $52.4 million across 5 years, with a median of $53.6 million in 2025.
• Annual changes were most pronounced in 2022 — Change in Cash slumped 144.27% — and 2024, when it soared 2084.58%.
• Alnylam Pharmaceuticals' Change in Cash stood at -$206.8 million in 2022, then fell by 6.52% to -$220.3 million in 2023, then surged by 39.25% to -$133.8 million in 2024, then soared by 224.03% to $166.0 million in 2025, then plunged by 67.7% to $53.6 million in 2026.
• The last three Change in Cash figures came in at $53.6 million (Q1 2026), $166.0 million (Q4 2025), and $376.9 million (Q3 2025), per Business Quant data.